PSTV vs. CTSO, ICCM, LUCD, XAIR, NUVO, AMIX, DRIO, DXR, ICAD, and MODD
Should you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Cytosorbents (CTSO), IceCure Medical (ICCM), Lucid Diagnostics (LUCD), Beyond Air (XAIR), Holdco Nuvo Group D.G (NUVO), Autonomix Medical (AMIX), DarioHealth (DRIO), Daxor (DXR), iCAD (ICAD), and Modular Medical (MODD). These companies are all part of the "surgical & medical instruments" industry.
Plus Therapeutics (NASDAQ:PSTV) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 2.3% of Plus Therapeutics shares are owned by insiders. Comparatively, 6.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Plus Therapeutics had 1 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Plus Therapeutics and 2 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.96 beat Plus Therapeutics' score of 0.30 indicating that Cytosorbents is being referred to more favorably in the news media.
Plus Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Plus Therapeutics has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cytosorbents has a net margin of -75.07% compared to Plus Therapeutics' net margin of -193.49%. Cytosorbents' return on equity of -129.89% beat Plus Therapeutics' return on equity.
Plus Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 261.99%. Cytosorbents has a consensus target price of $2.00, suggesting a potential upside of 122.20%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Plus Therapeutics is more favorable than Cytosorbents.
Cytosorbents received 373 more outperform votes than Plus Therapeutics when rated by MarketBeat users. Likewise, 79.13% of users gave Cytosorbents an outperform vote while only 60.58% of users gave Plus Therapeutics an outperform vote.
Summary
Cytosorbents beats Plus Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Plus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Plus Therapeutics Competitors List
Related Companies and Tools
